ScienceMachine Secures Strategic Funding to Accelerate AI-Driven Biomedical Discovery

ScienceMachine, a biotech startup founded in 2024, has secured funding from investors including Basis (VC), Opal Ventures, and Vento. The company, headquartered in San Francisco with a presence in London, has developed 'Sam', an AI-powered platform designed to automate and accelerate bioinformatics research. 

'Sam' functions as an AI data scientist, capable of structuring and analyzing complex biological data to uncover new insights, thereby enhancing R&D capabilities. The platform aims to support biotech and pharmaceutical companies in expediting their research processes and achieving breakthroughs more efficiently.

With a small team of 2-10 employees, ScienceMachine is poised to expand its operations and further develop its AI technologies.